NICLOSAMIDE

US Previously Marketed

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H8Cl2N2O4
Molecular Weight	327.12
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=C(C=C(Cl)C=C1)C(=O)NC2=C(Cl)C=C(C=C2)[N+]([O-])=O

InChI

InChIKey=RJMUSRYZPJIFPJ-UHFFFAOYSA-N

InChI=1S/C13H8Cl2N2O4/c14-7-1-4-12(18)9(5-7)13(19)16-11-3-2-8(17(20)21)6-10(11)15/h1-6,18H,(H,16,19)

HIDE SMILES / InChI

Molecular Formula	C13H8Cl2N2O4
Molecular Weight	327.12
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB06803
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/mmx/niclosamide.html

Niclosamide is an antihelminth used against tapeworm infections. It may act by the uncoupling of the electron transport chain to ATP synthase. The disturbance of this crucial metabolic pathway prevents creation of adenosine tri-phosphate (ATP), an essential molecule that supplies energy for metabolism. Niclosamide works by killing tapeworms on contact. Adult worms (but not ova) are rapidly killed, presumably due to uncoupling of oxidative phosphorylation or stimulation of ATPase activity. The killed worms are then passed in the stool or sometimes destroyed in the intestine. Niclosamide may work as a molluscicide by binding to and damaging DNA. Niclosamide is used for the treatment of tapeworm and intestinal fluke infections: Taenia saginata (Beef Tapeworm), Taenia solium (Pork Tapeworm), Diphyllobothrium latum (Fish Tapeworm), Fasciolopsis buski (large intestinal fluke). Niclosamide is also used as a molluscicide in the control of schistosomiasis. Niclosamide was marketed under the trade name Niclocide, now discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Staphylococcus aureus 65 Target ID: CHEMBL352 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25897961	Inhibitor 8228
Enterococcus faecium 5 Target ID: CHEMBL357 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25897961	Inhibitor 8228
Cytochrome P450 1A2 72 Target ID: CHEMBL3356 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11124226	Inhibitor 8228	2.7 µM [Ki]
Hymenolepis nana 2 Target ID: CHEMBL612450 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6841958	Inhibitor 8228
Target ID: Taenia saginata Sources: https://www.ncbi.nlm.nih.gov/pubmed/3425963	Inhibitor 8228
MCF7 21 Target ID: CHEMBL387 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27545321	Inhibitor 8228	45.0 µM [IC50]
DNA 247 Target ID: CHEMBL2366043 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12392939	Inhibitor 8228

Conditions

Condition	Modality	Highest Phase	Product
Diphyllobothriasis 2 Sources: https://www.drugs.com/cons/niclosamide.html	Curative	Approved 8360	NICLOCIDE Approved Use Diphyllobothriasis (treatment)—Niclosamide is indicated in the treatment of diphyllobothriasis caused by Diphyllobothrium latum (broad or fish tapeworm). Hymenolepiasis (treatment)—Niclosamide is indicated in the treatment of hymenolepiasis caused by Hymenolepis nana (dwarf tapeworm) and [H. diminuta (rat tapeworm)] . Taeniasis (treatment)—Niclosamide is indicated in the treatment of taeniasis caused by Taenia saginata (beef tapeworm) and [T. solium (pork tapeworm)] . [Dipylidiasis (treatment)]—Niclosamide is used in the treatment of dipylidiasis caused by Dipylidium caninum (dog and cat tapeworm). Launch Date 3.90095995E11
Hymenolepiasis 2 Sources: https://www.drugs.com/cons/niclosamide.html	Curative	Approved 8360	NICLOCIDE Approved Use Diphyllobothriasis (treatment)—Niclosamide is indicated in the treatment of diphyllobothriasis caused by Diphyllobothrium latum (broad or fish tapeworm). Hymenolepiasis (treatment)—Niclosamide is indicated in the treatment of hymenolepiasis caused by Hymenolepis nana (dwarf tapeworm) and [H. diminuta (rat tapeworm)] . Taeniasis (treatment)—Niclosamide is indicated in the treatment of taeniasis caused by Taenia saginata (beef tapeworm) and [T. solium (pork tapeworm)] . [Dipylidiasis (treatment)]—Niclosamide is used in the treatment of dipylidiasis caused by Dipylidium caninum (dog and cat tapeworm). Launch Date 3.90095995E11
Taeniasis 2 Sources: https://www.drugs.com/cons/niclosamide.html	Curative	Approved 8360	NICLOCIDE Approved Use Diphyllobothriasis (treatment)—Niclosamide is indicated in the treatment of diphyllobothriasis caused by Diphyllobothrium latum (broad or fish tapeworm). Hymenolepiasis (treatment)—Niclosamide is indicated in the treatment of hymenolepiasis caused by Hymenolepis nana (dwarf tapeworm) and [H. diminuta (rat tapeworm)] . Taeniasis (treatment)—Niclosamide is indicated in the treatment of taeniasis caused by Taenia saginata (beef tapeworm) and [T. solium (pork tapeworm)] . [Dipylidiasis (treatment)]—Niclosamide is used in the treatment of dipylidiasis caused by Dipylidium caninum (dog and cat tapeworm). Launch Date 3.90095995E11

C_max

Value	Dose	Co-administered	Analyte	Population
0.665 μg/mL EXPERIMENT https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e14536	2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered:		NICLOSAMIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
1413 ng × h/mL EXPERIMENT http://www.airitilibrary.com/Publication/alDetailedMesh?docid=10219498-200612-14-4-329-333-a	2 mg/kg single, intravenous dose: 2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		NICLOSAMIDE plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
6.7 h EXPERIMENT http://www.airitilibrary.com/Publication/alDetailedMesh?docid=10219498-200612-14-4-329-333-a	2 mg/kg single, intravenous dose: 2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		NICLOSAMIDE plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
1000 mg 3 times / day steady, oral Dose: 1000 mg, 3 times / day Route: oral Route: steady Dose: 1000 mg, 3 times / day Co-administed with:: enzalutamide(160 mg, oral, daily) Sources: https://pubmed.ncbi.nlm.nih.gov/29856824	unhealthy n = 2 Health Status: unhealthy Condition: castration-resistant prostate cancer Sex: M Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/29856824	DLT: Nausea, Vomiting... Dose limiting toxicities: Nausea (grade 3, 2 patients) Vomiting (grade 3, 2 patients) Diarrhea (grade 3, 2 patients) Colitis (grade 3, 2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/29856824

AEs

AE	Significance	Dose	Population
Colitis	grade 3, 2 patients DLT	1000 mg 3 times / day steady, oral Dose: 1000 mg, 3 times / day Route: oral Route: steady Dose: 1000 mg, 3 times / day Co-administed with:: enzalutamide(160 mg, oral, daily) Sources: https://pubmed.ncbi.nlm.nih.gov/29856824	unhealthy n = 2 Health Status: unhealthy Condition: castration-resistant prostate cancer Sex: M Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/29856824
Diarrhea	grade 3, 2 patients DLT	1000 mg 3 times / day steady, oral Dose: 1000 mg, 3 times / day Route: oral Route: steady Dose: 1000 mg, 3 times / day Co-administed with:: enzalutamide(160 mg, oral, daily) Sources: https://pubmed.ncbi.nlm.nih.gov/29856824	unhealthy n = 2 Health Status: unhealthy Condition: castration-resistant prostate cancer Sex: M Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/29856824
Nausea	grade 3, 2 patients DLT	1000 mg 3 times / day steady, oral Dose: 1000 mg, 3 times / day Route: oral Route: steady Dose: 1000 mg, 3 times / day Co-administed with:: enzalutamide(160 mg, oral, daily) Sources: https://pubmed.ncbi.nlm.nih.gov/29856824	unhealthy n = 2 Health Status: unhealthy Condition: castration-resistant prostate cancer Sex: M Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/29856824
Vomiting	grade 3, 2 patients DLT	1000 mg 3 times / day steady, oral Dose: 1000 mg, 3 times / day Route: oral Route: steady Dose: 1000 mg, 3 times / day Co-administed with:: enzalutamide(160 mg, oral, daily) Sources: https://pubmed.ncbi.nlm.nih.gov/29856824	unhealthy n = 2 Health Status: unhealthy Condition: castration-resistant prostate cancer Sex: M Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/29856824

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1709	inhibitor 1752 activator 21 substrate 1010	substrate 1193

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1509	CYP1A1 348 CYP1A2 1032 CYP1B1 92 CYP2B6 660 CYP2C8 688 CYP2C19 985 CYP2E1 648 CYP3A5 391 UGT1A1 418 UGT1A3 422 UGT1A4 347 UGT1A6 307 UGT1A7 236 UGT1A8 283 UGT1A9 380 UGT1A10 290 UGT2B4 249 UGT2B7 389 UGT2B15 203 UGT2B17 213

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1673	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/11124226/	yes [Ki 2.7 uM]
CYP2C9 1803	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/11124226/	yes [Ki 6 uM]
CYP2C9 1803	activator 210 Sources: https://pubmed.ncbi.nlm.nih.gov/11124226/	yes

Drug as victim

Target	Modality	Activity
CYP1B1 92	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 3.0	no
CYP2B6 660	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 3.0	no
CYP2C19 985	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 3.0	no
CYP2C8 688	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 3.0	no
CYP2C9 1010	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 3.0	no
CYP2D6 1193	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 3.0	no
CYP2E1 648	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 3.0	no
CYP3A4 1709	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 3.0	no
CYP3A5 391	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 3.0	no
UGT1A4 347	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 7.0	no
UGT1A6 307	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 7.0	no
UGT2B15 203	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 7.0	no
UGT2B17 213	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 7.0	no
UGT2B4 249	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 7.0	no
CYP1A1 348	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 6.0	yes
CYP1A2 1032	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 6.0	yes
UGT1A1 418	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 7.0	yes
UGT1A10 290	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 7.0	yes
UGT1A3 422	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 7.0	yes
UGT1A7 236	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 7.0	yes
UGT1A8 283	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 7.0	yes
UGT1A9 380	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 7.0	yes
UGT2B7 389	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/26068521/ Page: 7.0	yes

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B2-0772	http://www.3bsc.com/index/pro_info.php?id=20128
AA Blocks	AA0035B8	http://www.aablocks.com/goods/Goods/detail?id=AA0035B8
AHH Chemical co.,ltd	API-1745	http://www.ahhchemical.com/product/API-1745.html
AK Scientific, Inc. (AKSCI)	I012	http://www.aksci.com/item_detail.php?cat=I012
Aaron Chemicals	AR003630	http://www.aaronchem.com/50-65-7
AbMole Bioscience	M2055	http://www.abmole.com/products/niclosamide.html
Acadechem	ACDS-028814	http://www.acadechemical.com/product/103513
Achemtek	1ST20493	http://achemtek.com/50-65-7-2
Achemtek	0104-015424	http://www.achemtek.com/50-65-7
Acros Organics	AC461840250	https://www.fishersci.com/shop/products/niclosamide-97-acros-organics-1/AC461840250
Acros Organics	AC461841000	https://www.fishersci.com/shop/products/niclosamide-97-acros-organics/AC461841000
Alfa Chemistry	AP50657	https://reagents.alfa-chemistry.com/product/niclosamide-cas-50-65-7-cas-50-65-7-12166.html
Angene	AGN-PC-08WHBK	http://www.angenechemical.com/productshow/AGN-PC-08WHBK.html
ApexBio Technology	B2283	http://www.apexbt.com/niclosamide.html
Ark Pharm	AK173020	http://www.arkpharminc.com/products/50-65-7.html
Aurora Fine Chemicals LLC	K04.832.702	http://online.aurorafinechemicals.com/info?ID=K04.832.702
Aurum Pharmatech LLC	T7903	http://www.Aurumpharmatech.com/Product/ProductDetails/T7903
AvaChem Scientific	6587	https://www.avachem.com/productSearch.asp?6587
BioChemPartner	BCP22958	http://www.biochempartner.com/50-65-7-BCP22958
BioCrick	BCC5081	http://www.biocrick.com/Niclosamide-BCC5081.html
BioSynth	Q-201469	https://www.biosynth.com/en/products/life-science/enzyme-substrates-reagents/products/Q-201469.html
Chem Scene	CS-2618	http://www.chemscene.com/50-65-7.html
ChemMol	49409397	http://www.chemmol.com/chemmol/49409397.html
ChemMol	99097726	http://www.chemmol.com/chemmol/99097726.html
Chemenu	CM110596	http://www.chemenu.com/products/CM110596
Chemspace	CSSB00000764091	https://chem-space.com/CSSB00000764091
Debye Scientific	DB-051812	http://www.debyesci.com/cas_50-65-7.html
EMD Biosciences	481909	http://www.emdbiosciences.com/product/481909
EMD Millipore	481909	http://www.emdbiosciences.com/product/481909
Enamine	Z57902203	https://www.enaminestore.com/catalog/Z57902203
Finetech	FT-0603220	http://www.finetechnology-ind.com/prod/detail/pub/50-65-7.html
Glentham Life Sciences	GA5338	http://www.glentham.com/products/product/GA5338/
Hello Bio	HB1435	https://www.hellobio.com/niclosamide.html
LGC Standards	DRE-A15510000AL-100	https://www.lgcstandards.com/US/en/p/DRE-A15510000AL-100
LGC Standards	DRE-C15510000	https://www.lgcstandards.com/US/en/p/DRE-C15510000
LGC Standards	LGCFOR0361.00	https://www.lgcstandards.com/US/en/p/LGCFOR0361.00
LGC Standards	MM0361.00	https://www.lgcstandards.com/US/en/p/MM0361.00
Matrix Scientific	203850	https://www.matrixscientific.com/203850.html
MedChem Express	HY-B0497	https://www.medchemexpress.com/Niclosamide.html
Selleck Chemicals	S3030	http://www.selleckchem.com/products/niclosamide-niclocide.html
Sigma-Aldrich	N0560000_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/n0560000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	N3510_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/n3510?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S013157	http://www.sinfoobiotech.com/product/1016555
Smolecule	S548510	http://www.smolecule.com/products/s548510
Speranza Chemical Co., Ltd.	C057	http://www.speranzachem.com/products-50-65-7.html
Synblock Inc	SB19414	http://www.synblock.com/product/50-65-7.html
THE BioTek	bt-287919	https://www.thebiotek.com/product/inhibitors/bt-287919
Tocris	4079	https://www.tocris.com/products/niclosamide_4079
VladaChem	VL264556-100G	https://www.vladachem.com/product.php?products=50-65-7
Yuhao Chemical	HL1041	http://www.chemyuhao.com/50-65-7.html
abcr GmbH	AB372324	http://www.abcr.com/shop/en/AB372324
eNovation Chemicals	D672942	https://www.enovationchem.com/ProductDetails.asp?ProductID=D672942
eNovation Chemicals	D765674	https://www.enovationchem.com/ProductDetails.asp?ProductID=D765674
iChemical	EBD38831	http://www.ichemical.com/chemicals/cas-50-65-7
mcule	MCULE-9985514311	https://mcule.com/MCULE-9985514311/

PubMed

Title	Date	PubMed
[Climbing-upward inhibition of Oncomelania hupensis by niclosamide combination].	2001	12572067
Inhibition of stimulated Jurkat cell adenosine 3',5'-cyclic monophosphate synthesis by the immunomodulatory compound HR325.	2001 Jan 15	11163337
Effect of soil moisture and sample depth on pesticide photolysis.	2002 Apr 24	11958630
Transplasma membrane electron transport in Leishmania donovani promastigotes.	2002 Jan-Feb	11908895
Antiprotozoals effective in vitro against the scuticociliate fish pathogen Philasterides dicentrarchi.	2002 Jun 3	12113305
Generation and evaluation of a CYP2C9 heteroactivation pharmacophore.	2003 Dec	14557374
Measures for the prevention and control of Taenia solium taeniosis and cysticercosis.	2003 Jun	12781388
Investigations on the influence of helminth parasites on vaccination of chickens against Newcastle disease virus under village conditions.	2003 Oct	14620586
Human Monieziasis expansa: the first Egyptian parastic zoonosis.	2004 Aug	15287174
Polymeric controlled release formulations of niclosamide for control of Biomphalaria alexandrina, the vector snail of schistosomiasis.	2004 Feb 20	15468202
Aqueous photolysis of niclosamide.	2004 Feb 25	14969544
Adverse drug reactions to anthelmintics.	2004 Mar	14749518
Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs.	2004 May 15	15110833
[Treatment of intestinal helminthiasis with albendazole].	2005 Apr-Jun	15984617
Effect of 4-sulphonato-calix[n]arenes and cyclodextrins on the solubilization of niclosamide, a poorly water soluble anthelmintic.	2005 Sep 2	16146345
Lower-rim substituted calixarenes and their applications.	2007	17611612
Potential of some monoterpenoids and their new N-methyl carbamate derivatives against Schistosomiasis snail vector, Biomphalaria alexandrina.	2008 Nov	17692915
A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids.	2009 Aug	19225094
Spatial epidemiology in zoonotic parasitic diseases: insights gained at the 1st International Symposium on Geospatial Health in Lijiang, China, 2007.	2009 Feb 4	19193214
Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening.	2009 Jul 14	19597541

Patents

Sample Use Guides

In Vivo Use Guide

Adults—2 grams as a single dose. Treatment may be repeated in seven days if needed.

Route of Administration: Oral

In Vitro Use Guide

Niclosamide (0.2 ug/ml) was effective against Diplozoon paradoxum after an exposure of 90 min and 45 min in vitro.

Substance Class	Chemical Created by `admin` on `Wed Jul 05 22:51:42 UTC 2023` Edited by `admin` on `Wed Jul 05 22:51:42 UTC 2023`
Record UNII	8KK8CQ2K8G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NICLOSAMIDE

Official Name

English

NICLOSAMIDE [ISO]

Common Name

English

NICLOSAMIDE [HSDB]

Common Name

English

NICLOSAMIDE [EP MONOGRAPH]

Common Name

English

BAY 2353

Code

English

NICLOCIDE

Brand Name

English

Niclosamide [WHO-DD]

Common Name

English

BENZAMIDE, 5-CHLORO-N-(2-CHLORO-4-NITROPHENYL)-2-HYDROXY-

Systematic Name

English

niclosamide [INN]

Common Name

English

BAY-2353

Code

English

NICLOSAMIDE [ORANGE BOOK]

Common Name

English

NICLOSAMIDE, ANHYDROUS [EP IMPURITY]

Common Name

English

NICLOSAMIDE [USAN]

Common Name

English

NICLOSAMIDE [MART.]

Common Name

English

2',5-DICHLORO-4'-NITROSALICYLANILIDE

Systematic Name

English

NICLOSAMIDE [VANDF]

Common Name

English

NICLOSAMIDE ANHYDROUS [WHO-IP]

Common Name

English

NICLOSAMIDE [MI]

Common Name

English

5-CHLORO-N-(2-CHLORO-4-NITROPHENYL)-2-HYDROXYBENZAMIDE

Systematic Name

English

NICLOSAMIDUM ANHYDROUS [WHO-IP LATIN]

Common Name

English

NICLOSAMIDE, ANHYDROUS

Common Name

English

WR 46234

Code

English

NICLOSAMIDE [GREEN BOOK]

Common Name

English

NSC-178296

Code

English

NICLOSAMIDE (ANHYDROUS)

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C250